CanCure is an anticancer drug development startup venture developing antibodies that can revitalize patients own natural immune function to fight cancer. CanCure leading product CuraB-10 is ready to enter into clinical trials.
CanCure and its core technology was invented by Dr. Jennifer Wu, currently a Professor at the Medical University of South Carolina (MUSC) and Hollings Cancer Center.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/cancure-llc” connections=”true” suffix=””]
CanCures mAbs act on the immune modulators MICA and MICB, which are shed from tumor cells in soluble, immunosuppressive forms that bind and down-regulate NKG2D receptors on NK and other immune cells. When functional, NKG2D receptors activate the cells to trigger cytotoxicity and send co-stimulatory signals to augment the immune response and fight cancer or infection.
In Sep 2016, CanCure received NIH/NCI STTR Phase I small business award to advance the CanCure leading first-in-class cancer immunotherapeutic leading antibody CuraB-10 for clinical application.
Recover your password.
A password will be e-mailed to you.